Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three forms of nicotine replacement therapy (NRT): the transdermal nicotine patch (e.g., Nicoderm CQ), oral nicotine gum (e.g., Nicorette), and the prescription-only nicotine inhaler (e.g., Nicotrol Inhaler). The patch provides a steady, long-acting baseline level of nicotine throughout the day by absorption through the skin. The gum and inhaler are short-acting forms that deliver rapid relief from cravings by providing additional doses of nicotine as needed. This multi-modal approach targets both continuous withdrawal symptoms and acute cravings, improving smoking cessation rates compared to monotherapy. All three products act as agonists at nicotinic acetylcholine receptors in the brain, reducing withdrawal symptoms and cigarette cravings without exposing users to harmful tobacco smoke constituents[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotine patch + nicotine gum + nicotine inhaler.